Company intelligence / Profile preview

Alzinova AB

Mölndal, Västra Götaland, Swedenalzinova.com ↗

Ownership: Public · ALZ
Employees: ~5
Development stage: Phase 1

Overview

The company’s lead candidate, ALZ‑101, a therapeutic vaccine targeting amyloid-beta oligomers in Alzheimer’s disease, has completed part A of a phase 1b study with favorable safety and tolerability results and a high immune responder rate. Antibody levels increased with dosing. An extension study at higher doses is ongoing. Preparations for phase 2 are underway following positive regulatory feedback from FDA and EMA. The monoclonal antibody program ALZ‑201 remains in preclinical development[6][7][8][10].

Therapeutic areas: Neurology
Modalities: Active immunotherapies (therapeutic vaccines)Passive immunotherapies (monoclonal antibodies)
Industry: Biotech

Drug pipeline

2 assets

ALZ-101

1 more asset in the full pipeline.

Request access →

Partnerships

PolyPeptide Laboratories (manufacturing partner for clinical trial material)[8]

Financials

Market cap: $28M
Total revenue: $0
Enterprise value: $80.5M

Beyond the preview

Go deeper on Alzinova AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzinova AB.

Explore the full profile